AI Speeds Up Drug Discovery, but Human Biology and Wall Street's Clock Remain Obstacles

Artificial intelligence has accelerated the earliest, most laborious steps of drug discovery, yet it has so far failed to overturn the hardest realities of human biology or match the return timelines that investors expect. That tension is at the center of a widening debate over whether AI-designed medicines can translate laboratory speed into approved drugs and commercial value.